Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001641172-25-005093
Filing Date
2025-04-16
Accepted
2025-04-16 17:11:27
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 7880
2 ex99-1.htm EX-99.1 12624
  Complete submission text file 0001641172-25-005093.txt   22367
Mailing Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004
Business Address THREE BALA PLAZA EAST. SUITE 506 BALA CYNWYD PA 19004 844-511-9056
Larimar Therapeutics, Inc. (Subject) CIK: 0001374690 (see all company filings)

EIN.: 203857670 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-88225 | Film No.: 25843545
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address ONE BOSTON PLACE SUITE 2600 BOSTON MA 02108
Business Address ONE BOSTON PLACE SUITE 2600 BOSTON MA 02108 617-904-9195
Opaleye Management Inc. (Filed by) CIK: 0001595855 (see all company filings)

EIN.: 205648796 | State of Incorp.: MA | Fiscal Year End: 1231
Type: SCHEDULE 13G